Key result
VEGF inhibitors include ~20 compounds approved or under clinical study for cancer and related disorders.
Why the study?
Inhibition of the VEGF pathway is a widely pursued strategy to develop new therapeutics for VEGF-related disorders including cancer and other angiogenic diseases.
Inhibition of the VEGF pathway is a major therapeutic strategy, with numerous compounds approved or in development for the treatment of cancer and other angiogenesis-related disorders.
No takes yet. Share an insight, caveat, or question.
VEGF pathway inhibition remains a dominant oncology strategy; leaves open the need for dedicated cardio-oncology safety studies.
Pourgholami et al. (2008) conducted a review in Cancer. VEGF inhibitors was evaluated. Over twenty compounds with anti-angiogenic properties targeting the VEGF pathway are either approved or under clinical study for the treatment of cancer and related disorders.